ABSTRACT
Background Seroprevalence studies provide an accurate measure of SARS-CoV-2 spread at a population level and the number of undiagnosed individuals. Repeated cross-sectional sero-studies are encouraged to monitor the spread of the virus. The aim of this study is to assess the seroprevalence rate among a random sample of Palestinians residing in the West Bank region of Palestine.
Methods This second round cross-sectional study involved 1451 participants, who agreed to be interviewed and answer the questionnaire, where 910 of them agreed to participate in the sero- study and donate a blood sample to be tested for antibodies. The sample was randomly selected from the adult population, 18 years or older, living the West Bank region of Palestine.
Serological tests for 910 adequate serum samples were done using immunoassays for detection of antibodies against SARS-CoV-2. Sociodemographic information and medical history data was collected.
Results Study findings indicate that as of October 2021, a seroprevalence rate of 75.9% (30% due to infection with Covid-19 virus and 45.9% due to vaccination), 95% CI (73.1-78.7). The results indicate that the prevalence of antibodies among those who are unvaccinated and undiagnosed was 45.2% with 95% CI (39.9-50.5%).
The average age of participants was 37.6 years old. 49.2% were females and 50.8% were males. In relation to COVID-19, 13.6% of respondents reported getting infected by Covid-19 with statistically significant difference (P_value=0.001) between males (10.7%) and females (16.5%).
. In terms of vaccination, 52.8% of respondents reported getting vaccinated with an important difference between males (64.3%) and females (40.9%), (P-value=0.000).
Conclusion Our findings reveal a drastic rise in seroprevalence of SARS-CoV-2 antibodies due to infection and vaccination. This information is useful for assessing the degree of herd immunity among the adult population and provides better understanding of the pandemic. Population-based seroprevalence studies should be conducted periodically to monitor the SARS-CoV-2 seroprevalence in Palestine and inform policymakers about the efficacy of the surveillance system and the public compliance with vaccination policies especially among females
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Arab American University of Palestine (www.aaup.edu)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data collection was conducted by healthcare professionals at Arab American University of Palestine following standardized health protocols (World Health, 2020). Approval from the National Ethical Committee was obtained (PHRC/HC/737/20). Written informed consent was obtained from all participants before the interview and the blood sampling and approval of utilization of tests was obtained from Medicare laboratories Participation was completely voluntary and all participants were informed that all the information collected would be anonymous and treated as confidential.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
faisal.awartani{at}gmail.com
Data Availability
All data produced in the present study are available upon reasonable request to the authors
